Trial · NCT01998633
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Overall Survival (OS) | Hematopoietic Stem Cell Transplant | 1 year OS | 80.4 | 95% Confidence Interval 68.6 to 88.2 | percentage of participants |
| Percentage of Participants With Overall Survival (OS) | Hematopoietic Stem Cell Transplant | 18 month OS | 66.7 | 95% Confidence Interval 52.9 to 77.3 | percentage of participants |
| Percentage of Participants With Overall Survival (OS) by Disease Type | Hemophagocytic Lymphohistiocytosis (HLH) | 1 year OS | 82.4 | 95% Confidence Interval 68.4 to 90.6 | percentage of participants |
| Percentage of Participants With Overall Survival (OS) by Disease Type | Other Primary Immune Deficiencies (PID) | 1 year OS | 75.0 | 95% Confidence Interval 47.4 to 89.5 | percentage of participants |
| Percentage of Participants With Overall Survival (OS) by Disease Type | Hemophagocytic Lymphohistiocytosis (HLH) | 18 month OS | 68.0 | 95% Confidence Interval 51.8 to 79.7 | percentage of participants |
| Percentage of Participants With Overall Survival (OS) by Disease Type | Other Primary Immune Deficiencies (PID) | 18 month OS | 62.5 | 95% Confidence Interval 32.7 to 82.0 | percentage of participants |
| Percentage of HLH Participants With HLH Reactivation Post-Transplant | Hematopoietic Stem Cell Transplant | 14.7 | 95% Confidence Interval 5.2 to 28.7 | percentage of participants | |
| Percentage of Participants With Neutrophil Engraftment | Hematopoietic Stem Cell Transplant | 100.0 | 95% Confidence Interval 90.8 to 100.0 | percentage of participants | |
| Percentage of Participants With Platelet Engraftment | Hematopoietic Stem Cell Transplant | 88.9 | 95% Confidence Interval 73.3 to 95.6 | percentage of participants | |
| Percentage of Participants Alive With Sustained Engraftment | Hematopoietic Stem Cell Transplant | 39.1 | 95% Confidence Interval 25.1 to 54.6 | percentage of participants | |
| Percentage of Participants Alive With Sustained Engraftment by Disease Type | Hemophagocytic Lymphohistiocytosis (HLH) | 41.2 | 95% Confidence Interval 24.7 to 59.3 | percentage of participants | |
| Percentage of Participants Alive With Sustained Engraftment by Disease Type | Other Primary Immune Deficiencies (PID) | 33.3 | 95% Confidence Interval 9.9 to 65.1 | percentage of participants | |
| Number of Participants With Acute Graft-Versus-Host Disease (GVHD) | Hematopoietic Stem Cell Transplant | Grade 0 or I | 35 | Participants | |
| Number of Participants With Acute Graft-Versus-Host Disease (GVHD) | Hematopoietic Stem Cell Transplant | Grade II | 3 | Participants | |
| Number of Participants With Acute Graft-Versus-Host Disease (GVHD) | Hematopoietic Stem Cell Transplant | Grade III | 5 | Participants | |
| Number of Participants With Acute Graft-Versus-Host Disease (GVHD) | Hematopoietic Stem Cell Transplant | Grade IV | 3 | Participants | |
| Percentage of Participants With Grade II-IV and Grade III-IV Acute GVHD | Hematopoietic Stem Cell Transplant | Grade II-IV Acute GVHD at Day 100 | 17.4 | 95% Confidence Interval 8.1 to 29.7 | percentage of participants |
| Percentage of Participants With Grade II-IV and Grade III-IV Acute GVHD | Hematopoietic Stem Cell Transplant | Grade II-IV Acute GVHD at 6 Months | 26.1 | 95% Confidence Interval 14.4 to 39.4 | percentage of participants |
| Percentage of Participants With Grade II-IV and Grade III-IV Acute GVHD | Hematopoietic Stem Cell Transplant | Grade III-IV Acute GVHD at Day 100 | 10.9 | 95% Confidence Interval 4.0 to 21.3 | percentage of participants |
| Percentage of Participants With Grade II-IV and Grade III-IV Acute GVHD | Hematopoietic Stem Cell Transplant | Grade III-IV Acute GVHD at 6 Months | 17.4 | 95% Confidence Interval 8.1 to 29.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01998633/results